Cytomegalovirus prophylaxis in kidney transplant recipients.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in the transplant population. It is important to understand the nature of CMV and its effect on the immunosuppressed host. In the last decade, several prophylactic drugs have been tested in transplant recipients. Most studies found that CMV prophylactic drugs protect transplant recipients to some degree. This article reviews the pathophysiology of CMV, the immunosuppressed host, and prophylaxis.
Lott
S
S
D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D016867:Immunocompromised Host; D017053:Infection Control; D016030:Kidney Transplantation / Q000009:adverse effects*; D009730:Nursing Assessment; D012307:Risk Factors